Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE ®) - an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A

U. Martinowitz, J. Bjerre, B. Brand, R. Klamroth, M. Misgav, M. Morfini, E. Santagostino, A. Tiede, D. Viuff

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Recombinant coagulation factor VIII (rFVIII) concentrates provide a safe and efficacious replacement therapy for treatment and prevention of bleeding in patients with severe haemophilia A. The aim of this study was to compare the pharmacokinetic (PK) and safety profiles of two serum-free rFVIII products: N8, a new rFVIII manufactured by Novo Nordisk and Advate ®, a marketed product. Patients with severe haemophilia A with >150 exposure days to FVIII, without current or past inhibitors, were enrolled in an open-label, first human dose (FHD), multicentre trial. Twenty-three patients first received a single dose of 50IUkg -1 body weight Advate ® followed by 50IUkg -1 body weight N8 at the next visit. A 4-day washout period was required prior to each dosing. Blood samples for PK and safety analyses were drawn prior to dosing and at intervals up until 48h postdosing. The PK parameters were based on FVIII clotting activity (FVIII:C) measurements. Occurrence of adverse events was closely monitored. The mean profiles of FVIII:C and all primary and secondary parameters for Advate ® and N8 were comparable. The 90% CI for the treatment ratio (Advate ®/N8) for all primary endpoints (incremental recovery, t 1/2, AUC and Cl), and the secondary endpoints (AUC last and C max) were within the bioequivalence interval of 0.8-1.25. There were no safety concerns in the study and no reports of inhibitor formation in the 72-h period following exposure to a single N8 dose. In conclusion, N8 is bioequivalent to Advate ®. Furthermore, N8 is well tolerated in the FHD trial.

Original languageEnglish
Pages (from-to)854-859
Number of pages6
JournalHaemophilia
Volume17
Issue number6
DOIs
Publication statusPublished - Nov 2011

Fingerprint

Therapeutic Equivalency
Factor VIII
Hemophilia A
Pharmacokinetics
Safety
Area Under Curve
Serum
Body Weight
Multicenter Studies
Therapeutics
Hemorrhage
recombinant factor VIII N8

Keywords

  • Bioequivalence
  • First human dose
  • Haemophilia A
  • Open label
  • Pharmacokinetics
  • RFVIII

ASJC Scopus subject areas

  • Hematology
  • Genetics(clinical)
  • Medicine(all)

Cite this

Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE ®) - an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A. / Martinowitz, U.; Bjerre, J.; Brand, B.; Klamroth, R.; Misgav, M.; Morfini, M.; Santagostino, E.; Tiede, A.; Viuff, D.

In: Haemophilia, Vol. 17, No. 6, 11.2011, p. 854-859.

Research output: Contribution to journalArticle

Martinowitz, U. ; Bjerre, J. ; Brand, B. ; Klamroth, R. ; Misgav, M. ; Morfini, M. ; Santagostino, E. ; Tiede, A. ; Viuff, D. / Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE ®) - an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A. In: Haemophilia. 2011 ; Vol. 17, No. 6. pp. 854-859.
@article{f17bc68261834279ba674d01813778f9,
title = "Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE {\circledR}) - an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A",
abstract = "Recombinant coagulation factor VIII (rFVIII) concentrates provide a safe and efficacious replacement therapy for treatment and prevention of bleeding in patients with severe haemophilia A. The aim of this study was to compare the pharmacokinetic (PK) and safety profiles of two serum-free rFVIII products: N8, a new rFVIII manufactured by Novo Nordisk and Advate {\circledR}, a marketed product. Patients with severe haemophilia A with >150 exposure days to FVIII, without current or past inhibitors, were enrolled in an open-label, first human dose (FHD), multicentre trial. Twenty-three patients first received a single dose of 50IUkg -1 body weight Advate {\circledR} followed by 50IUkg -1 body weight N8 at the next visit. A 4-day washout period was required prior to each dosing. Blood samples for PK and safety analyses were drawn prior to dosing and at intervals up until 48h postdosing. The PK parameters were based on FVIII clotting activity (FVIII:C) measurements. Occurrence of adverse events was closely monitored. The mean profiles of FVIII:C and all primary and secondary parameters for Advate {\circledR} and N8 were comparable. The 90{\%} CI for the treatment ratio (Advate {\circledR}/N8) for all primary endpoints (incremental recovery, t 1/2, AUC and Cl), and the secondary endpoints (AUC last and C max) were within the bioequivalence interval of 0.8-1.25. There were no safety concerns in the study and no reports of inhibitor formation in the 72-h period following exposure to a single N8 dose. In conclusion, N8 is bioequivalent to Advate {\circledR}. Furthermore, N8 is well tolerated in the FHD trial.",
keywords = "Bioequivalence, First human dose, Haemophilia A, Open label, Pharmacokinetics, RFVIII",
author = "U. Martinowitz and J. Bjerre and B. Brand and R. Klamroth and M. Misgav and M. Morfini and E. Santagostino and A. Tiede and D. Viuff",
year = "2011",
month = "11",
doi = "10.1111/j.1365-2516.2011.02495.x",
language = "English",
volume = "17",
pages = "854--859",
journal = "Haemophilia",
issn = "1351-8216",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "6",

}

TY - JOUR

T1 - Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE ®) - an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A

AU - Martinowitz, U.

AU - Bjerre, J.

AU - Brand, B.

AU - Klamroth, R.

AU - Misgav, M.

AU - Morfini, M.

AU - Santagostino, E.

AU - Tiede, A.

AU - Viuff, D.

PY - 2011/11

Y1 - 2011/11

N2 - Recombinant coagulation factor VIII (rFVIII) concentrates provide a safe and efficacious replacement therapy for treatment and prevention of bleeding in patients with severe haemophilia A. The aim of this study was to compare the pharmacokinetic (PK) and safety profiles of two serum-free rFVIII products: N8, a new rFVIII manufactured by Novo Nordisk and Advate ®, a marketed product. Patients with severe haemophilia A with >150 exposure days to FVIII, without current or past inhibitors, were enrolled in an open-label, first human dose (FHD), multicentre trial. Twenty-three patients first received a single dose of 50IUkg -1 body weight Advate ® followed by 50IUkg -1 body weight N8 at the next visit. A 4-day washout period was required prior to each dosing. Blood samples for PK and safety analyses were drawn prior to dosing and at intervals up until 48h postdosing. The PK parameters were based on FVIII clotting activity (FVIII:C) measurements. Occurrence of adverse events was closely monitored. The mean profiles of FVIII:C and all primary and secondary parameters for Advate ® and N8 were comparable. The 90% CI for the treatment ratio (Advate ®/N8) for all primary endpoints (incremental recovery, t 1/2, AUC and Cl), and the secondary endpoints (AUC last and C max) were within the bioequivalence interval of 0.8-1.25. There were no safety concerns in the study and no reports of inhibitor formation in the 72-h period following exposure to a single N8 dose. In conclusion, N8 is bioequivalent to Advate ®. Furthermore, N8 is well tolerated in the FHD trial.

AB - Recombinant coagulation factor VIII (rFVIII) concentrates provide a safe and efficacious replacement therapy for treatment and prevention of bleeding in patients with severe haemophilia A. The aim of this study was to compare the pharmacokinetic (PK) and safety profiles of two serum-free rFVIII products: N8, a new rFVIII manufactured by Novo Nordisk and Advate ®, a marketed product. Patients with severe haemophilia A with >150 exposure days to FVIII, without current or past inhibitors, were enrolled in an open-label, first human dose (FHD), multicentre trial. Twenty-three patients first received a single dose of 50IUkg -1 body weight Advate ® followed by 50IUkg -1 body weight N8 at the next visit. A 4-day washout period was required prior to each dosing. Blood samples for PK and safety analyses were drawn prior to dosing and at intervals up until 48h postdosing. The PK parameters were based on FVIII clotting activity (FVIII:C) measurements. Occurrence of adverse events was closely monitored. The mean profiles of FVIII:C and all primary and secondary parameters for Advate ® and N8 were comparable. The 90% CI for the treatment ratio (Advate ®/N8) for all primary endpoints (incremental recovery, t 1/2, AUC and Cl), and the secondary endpoints (AUC last and C max) were within the bioequivalence interval of 0.8-1.25. There were no safety concerns in the study and no reports of inhibitor formation in the 72-h period following exposure to a single N8 dose. In conclusion, N8 is bioequivalent to Advate ®. Furthermore, N8 is well tolerated in the FHD trial.

KW - Bioequivalence

KW - First human dose

KW - Haemophilia A

KW - Open label

KW - Pharmacokinetics

KW - RFVIII

UR - http://www.scopus.com/inward/record.url?scp=84857936508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857936508&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2516.2011.02495.x

DO - 10.1111/j.1365-2516.2011.02495.x

M3 - Article

VL - 17

SP - 854

EP - 859

JO - Haemophilia

JF - Haemophilia

SN - 1351-8216

IS - 6

ER -